Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2026-05-25 Board/Management Inform…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appointment of 2 non-Executive Directors 3 pages 136.5KB
Board/Management Information Classification · 93% confidence The document is an ASX announcement titled “Imugene Announces Board Enhancement,” detailing the appointment of two new non-executive directors, their backgrounds, effective dates, and related board composition and remuneration committee actions. This is clearly an announcement of changes to the company’s board of directors, which falls under Board/Management Information.
2026-05-25 English
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract 4 pages 205.2KB
Regulatory Filings Classification · 91% confidence The document is an ASX announcement by Imugene Limited describing clinical trial data and response rates for its CAR T therapy presented at ASCO 2026. It contains no financial statements, earnings figures, management discussion of overall results, or request for shareholder votes. It is not a full report, earnings release, proxy statement, investor presentation with slides, nor an interim or annual report. This is a miscellaneous regulatory disclosure announcing clinical data to the market, so it falls under general regulatory announcements (RNS).
2026-05-21 English
Change of Director's Interest Notice - PH 2 pages 44.8KB
Director's Dealing Classification · 90% confidence The document is an ASX Appendix 3Y "Change of Director's Interest Notice," detailing a director’s security holdings, acquisitions, disposals, and the nature of the interests. This matches a director’s personal share transactions (insider trades), which falls under the Director’s Dealing category.
2026-05-17 English
Change of Director's Interest Notice - LC 2 pages 5.7KB
Director's Dealing Classification · 93% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” detailing a director’s securities transactions and relevant interests under listing rule 3.19A.2. This corresponds exactly to insider share dealings by a director, fitting the “Director’s Dealing” category.
2026-05-14 English
Ceasing to be a substantial holder 3 pages 419.4KB
Major Shareholding Notification Classification · 90% confidence The document is an Australian Form 605 “Notice of ceasing to be a substantial holder” under the Corporations Act 2001. It details changes in relevant interests, dates of on-market sales, dilution, and the end of a substantial shareholding. This is a notification of changes in significant share ownership levels. Therefore, it is classified as Major Shareholding Notification (MRQ).
2026-05-11 English
Application for quotation of securities - IMU 8 pages 21.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the securities to be quoted, issue dates, number of securities, and references prior Appendix 3B filings. The content focuses on the issuance and quotation of new securities, including options and attaching options, and mentions shareholder approval at an EGM. There are no financial statements or detailed financial performance data, nor is this a report or presentation. This type of document is a regulatory announcement related to capital changes and securities issuance. According to the filing definitions, announcements about new share issues or capital changes fall under the category 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a brief announcement of a report (RPA) or a general regulatory filing (RNS). Therefore, the correct classification is SHA with high confidence.
2026-05-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.